Wikipedia -WSS

Wikipedia

author：knowledge 2025-10-01 15:40:02 - browse：899

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke last week at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called aficamten, said Wednesday that it had agreed to pay biotech firm Royalty Pharma a higher royalty on the medicine in return for up to $575 million, which will be used to fund the marketing of the drug and Cytokinetics’ ongoing research and development efforts.

Cytokinetics shares fell nearly 10% in after-hours trading after the announcement, which investors viewed as lowering the odds that the company will be purchased by a larger pharmaceutical company.

The firm also said that it would be raising $500 million through a stock sale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Sage considers ways to reduce costs following FDA rejection

leisure time

WSS

Election results set back Medicaid expansion plans

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Creating egg and sperm cells from stem cells raises ethical issues

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Intermittent fasting comes with a heart risk? Not so fast

hotspot

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Duchenne breakthrough therapy leaves behind pioneering families

Baby aspirin cuts fat buildup in liver disease patients, in small study

Medical records are filled with copy

Trump used to be more articulate. What could explain the change?

Hepatitis C has a cure — but many Americans still lack access to it

Intermittent fasting comes with a heart risk? Not so fast

George Santos makes 1st court appearance after pleading not guilty to 13 counts

It was time to plan for my old age. If only I could stop crying

Walensky prepares to leave CDC — and Congress — behind

Failure, not just success, should guide future doctors

explore

With heat waves through August, officials warn of health risks

Stop the failed accountable care organization experiment

App could help diagnose ear infections more accurately — and at home

UnitedHealth increases loan offers after Change Healthcare outage

U.K. researchers warn about biases in medical devices, algorithms

Virtual Event: March of the Biosimilars

explore

leisure time

hotspot

leisure time